| Filed On | Filing |
|---|---|
| 21 Nov 2025 |
8-K/A: Financial Statements and Exhibits
The following unaudited pro forma combined financial information has been prepared in accordance with Article 11 of Regulation S-X under the Securities Act of 1933, as amended, and presents the pro forma effects of the acquisition (such ... |
| 22 Nov 2023 |
8-K/A: Changes in Registrant's Certifying Accountant
We were previously principal accountants for NRX Pharmaceuticals, Inc. and subsidiaries (the Company) and, under the date of March 31, 2023, we reported on the consolidated financial statements of the Company as of and for the years ende... |
| 07 Jun 2023 |
8-K/A: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This Securities Purchase Agreement (this “Agreement”) is dated as of June 6, 2023, between NRX Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including it... |
| 14 Mar 2023 |
8-K/A: Entry into a Material Definitive Agreement; Regulation FD Disclosure
This Securities Purchase Agreement (this “Agreement”) is dated as of March 8, 2023 between NRX Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including it... |
| 11 Jan 2021 | 8-K/A: Notice of Delisting or Failure to Satisfy a Listing Rule |
Loading...
